ENTRADA THERAPEUTICS, INC. Financing Cash Flow
ENTRADA THERAPEUTICS, INC. (TRDA) reported Financing Cash Flow of $450.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $350.00K, a 3.86% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $100.00K, a 71.43% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $192.00K, a 86.31% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $8.00K.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $887.00K, a 99.14% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $102.96M, a 389.44% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $21.04M, a 4291.86% increase from fiscal 2022.
- ENTRADA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $479.00K, a 99.84% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $350.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $450.00K 10-Q · filed 2026-08-05 | $642.00K derived: sum of 3 quarters · filed 2026-08-05 | $650.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-07 | $292.00K derived: sum of 2 quarters · filed 2026-05-07 | $300.00K derived: sum of 3 quarters · filed 2026-05-07 | $637.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $192.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $200.00K derived: sum of 2 quarters · filed 2026-02-26 | $537.00K derived: sum of 3 quarters · filed 2026-08-05 | $887.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $345.00K derived: sum of 2 quarters · filed 2026-08-05 | $695.00K 10-Q · filed 2025-11-06 | $2.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $337.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $687.00K 10-Q · filed 2026-08-05 | $2.09M derived: sum of 3 quarters · filed 2026-08-05 | $2.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $350.00K 10-Q · filed 2026-05-07 | $1.75M derived: sum of 2 quarters · filed 2026-05-07 | $1.74M derived: sum of 3 quarters · filed 2026-05-07 | $103.11M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.39M derived: sum of 2 quarters · filed 2026-02-26 | $102.76M derived: sum of 3 quarters · filed 2026-02-26 | $102.96M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $101.36M derived: sum of 2 quarters · filed 2025-11-06 | $101.56M 10-Q · filed 2025-11-06 | $102.25M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $101.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $101.57M 10-Q · filed 2025-08-06 | $102.26M derived: sum of 3 quarters · filed 2025-08-06 | $102.63M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $206.00K 10-Q · filed 2025-05-08 | $896.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.26M derived: sum of 3 quarters · filed 2025-05-08 | $1.71M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $690.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.06M derived: sum of 2 quarters · filed 2025-02-27 | $1.50M derived: sum of 3 quarters · filed 2025-02-27 | $21.04M 10-K · filed 2025-02-27 |
| 2023-09-30 | $368.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $811.00K derived: sum of 2 quarters · filed 2024-11-05 | $20.35M 10-Q · filed 2024-11-05 | $20.70M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $443.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $19.98M 10-Q · filed 2024-08-13 | $20.34M derived: sum of 3 quarters · filed 2024-08-13 | $20.40M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $19.54M 10-Q · filed 2024-05-07 | $19.89M derived: sum of 2 quarters · filed 2024-05-07 | $19.95M derived: sum of 3 quarters · filed 2024-05-07 | $19.96M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $358.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $418.00K derived: sum of 2 quarters · filed 2024-03-13 | $429.00K derived: sum of 3 quarters · filed 2024-03-13 | $479.00K 10-K · filed 2024-03-13 |
| 2022-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $71.00K derived: sum of 2 quarters · filed 2023-11-07 | $121.00K 10-Q · filed 2023-11-07 | $190.88M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $61.00K 10-Q · filed 2023-08-08 | $190.82M derived: sum of 3 quarters · filed 2023-08-08 | $190.92M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $50.00K 10-Q · filed 2023-05-10 | $190.81M derived: sum of 2 quarters · filed 2023-05-10 | $190.91M derived: sum of 3 quarters · filed 2023-05-10 | $191.13M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $190.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $190.86M derived: sum of 2 quarters · filed 2023-03-06 | $191.08M derived: sum of 3 quarters · filed 2023-03-06 | $307.46M 10-K · filed 2023-03-06 |
| 2021-09-30 | $106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $321.00K derived: sum of 2 quarters · filed 2022-11-07 | $116.71M 10-Q · filed 2022-11-07 | $116.86M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $215.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $116.60M 10-Q · filed 2022-08-11 | $116.75M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $116.39M 10-Q · filed 2022-05-12 | $116.53M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $50.09M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $49.94M 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |